National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 63 of 66
Tissue Acquisition for Molecular Diagnostics
NCT00001580
Edrecolomab in Treating Patients With Stage II Colon Cancer
NCT00002968
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
NCT00002796
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
NCT00001575
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019214
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
NCT00001574
A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
NCT00001573
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
NCT00001571
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
NCT00001570
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
NCT00002925
Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
NCT00002909
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities
NCT00001568
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
NCT00019136
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
NCT00001572
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
NCT00001563
A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia
NCT00001567
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
NCT00002912
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
NCT00001569
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00019188
Docetaxel in Treating Children With Recurrent Solid Tumors
NCT00002825
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
NCT00001560
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
NCT00001564
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
NCT00002913
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004029
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
NCT00001566
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy
NCT00001565
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
NCT00001561
Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection
NCT00019240
Perillyl Alcohol in Treating Patients With Refractory Cancer
NCT00002862
Monoclonal Antibody Therapy in Treating Patients With Leukemia
NCT00019227
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
NCT00002852
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
NCT00001503
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
NCT00001512
Carmustine in Treating Patients With Recurrent Malignant Glioma
NCT00004028
Biomarkers for Oral Cancer
NCT00341497
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
NCT00590785
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma
NCT00019175
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT00002798
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
NCT00019201
Analysis of NF2 Mutations in Radiation-Related Neural Tumors
NCT00340496
Gemcitabine in Treating Children With Refractory Solid Tumors
NCT00005577
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00002725
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
NCT00001507
A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor
NCT00001509
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
NCT00002759
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients
NCT00001504
Specimens From Normal Controls
NCT00341211
Immunotoxin in Treating Patients With Leukemia or Lymphoma
NCT00002765
Topotecan in Treating Children With Refractory Leukemia
NCT00002705
Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits
NCT00001500
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.